Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Dec 1;21(6):553-558.
doi: 10.1097/ACI.0000000000000787.

Antibody therapy for COVID-19

Lennart Hammarström  1 , Harold Marcotte  2 , Antonio Piralla  3 , Fausto Baldanti  3   4 , Qiang Pan-Hammarström  1
Affiliations
Review

Antibody therapy for COVID-19

Lennart Hammarström et al. Curr Opin Allergy Clin Immunol. .

Abstract

Purpose of review: To provide an update of the current state of antibody therapy for Severe Acute Respiratory Syndrome Coronavirus 2 infection that has progressed immensely in a very short time period.

Recent findings: Limited clinical effect of classical passive immunotherapy (plasma therapy, hyperimmune immunoglobulin [IgG] preparations) whereas monoclonal antibody therapy, if initiated early in the disease process, shows promising results.

Summary: Although antibody therapy still remains to be fully explored in patients with COVID-19, a combination of IgG monoclonal antibodies against the receptor-binding domain of the spike protein currently appears to provide the best form of antibody therapy, Immunoglobulin A dimers and Immunoglobulin M pentamers also show promising preliminary therapeutic results.

PubMed Disclaimer

Conflict of interest statement

There are no conflicts of interest.

Figures

Box 1
Box 1
no caption available
See this image and copyright information in PMC

References

    1. Hammarström L, Abolhassani H, Baldanti F, et al. . Development of passive immunity against SARS-CoV-2 for management of immunodeficient patients-a perspective. J Allergy Clin Immunol 2020; 146:58–60. - PMC - PubMed
    1. Schwaiger J, Karbiener M, Aberham C, et al. . No SARS-CoV-2 neutralization by intravenous immunoglobulins produced from plasma collected before the 2020 pandemic. J Infect Dis 2020; 222:1960–1964. - PMC - PubMed
    1. Fante CD, Franchini M, Baldanti F, et al. . A retrospective study assessing the characteristics of COVID-19 convalescent plasma donors and donations. Transfusion 2021; 61:830–838. - PMC - PubMed
    1. Farcet MR, Karbiener M, Schwaiger J, et al. . Rapidly Increasing SARS-CoV-2 neutralization by intravenous immunoglobulins produced from plasma collected during the 2020 pandemic. J Inf Dis 2021; https://doi-org.proxy.kib.ki.se/10.1093/infdis/jiab142https://doi-org.proxy.kib.ki.se/10.1093/infdis/jiab142. [Online ahead of print]. - DOI - DOI - PMC - PubMed
    1. Cheng Y, Wong R, Soo YOY, et al. . Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis 2005; 24:44–46. - PMC - PubMed

Publication types

LinkOut - more resources